FDA approves isatuximab-irfc for patients with relapsed refractory myeloma
The U.S. Food and Drug Administration (FDA) has approved isatuximab-irfc (Sarclisa®) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.